MP13-Resistencias a Antiretrovirales

Información
Miembros
Publicaciones
Proyectos
Ensayos clínicos

The group coordinates the Spanish HIV Research Network Work Package on subtypes and resistance and contributes with several European organizations on HIV resistance (ESAR-SPREAD, Eurocord-CHAIN, EuRESIST-INTEGRATE) and hepatitis resistance (SHARED, HEPCARE). The group has been actively involved in recent research on Transmitted Drug Resistance in Spain and Europe, on genotypic investigation on HIV viral Tropism, on clinical significance of HIV low and very low-level viraemia, and on molecualr epidemiology of HIV ti guide public helath interventions. The group is actively involved in hepatitis C virus research activities, coordianting several activities in GEHEP (Spanish Viral Hepatitis Study Group of the Clinical Microbiology & Infectious diseases Spanish Society), and coordinator of HEPCRESP, the Spanish national cohort on HCV resistance to new DAAs. The group is also in the Sterring Comittee of HEPCARE (Europe) and SHARED (Global) hepatitis

Líneas de investigación

Eliminación de hepatitis C
Epidemiología molecular de VIH
Microbiota e inmunomodulación
Microbiota y enfermedad
Microbiota y probióticos
Resistencias a Antirretrovirales
Resistencias en VHC

Redes de investigación

RIS - Red Española de Investigación en Sida
CIBERINFEC - Centro de Investigación Biomédica en Red de Enfermedades Infecciosas

Palabras clave

VIH, Hepatitis C, Microbiota.

RUBEN CEBRIAN CASTILLO

ORCID

ANGEL CARAZO GALLEGO

ORCID

Mª DOLORES MERIDA DEL CAÑO

JOSE ANTONIO SANCHEZ ALVAREZ

MARTA ALVAREZ ESTEVEZ

ORCID

NATALIA CHUECA PORCUNA

ORCID

ADOLFO DE SALAZAR GONZALEZ

ANA FUENTES LOPEZ

FEDERICO GARCIA GARCIA

FERNANDO GARCIA GARCIA

JOSEFA LOPEZ BUENO

Nakanishi, T; Pigazzini, S; Degenhardt, F; Cordioli, M; Butler-Laporte, G; Maya-Miles, D; Bujanda, L; Bouysran, Y; Niemi, MEK; Palom, A; Ellinghaus, D; Khan, A; Martinez-Bueno, M; Rolker, S; Amitrano, S; Tato, LR; Fava, F; Spinner, CD; Prati, D; Bernardo,

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

JOURNAL OF CLINICAL INVESTIGATION, 2021;

FI:14,808; D1

Vezza, T; Garrido-Mesa, J; Diez-Echave, P; Hidalgo-Garcia, L; Ruiz-Malagon, AJ; Garcia, F; Sanchez, M; Toral, M; Romero, M; Duarte, J; Guillamon, E; Banos, A; Moron, R; Galvez, J; Rodriguez-Nogales, A; Rodriguez-Cabezas, ME

Allium-Derived Compound Propyl Propane Thiosulfonate (PTSO) Attenuates Metabolic Alterations in Mice Fed a High-Fat Diet through Its Anti-Inflammatory and Prebiotic Properties.

NUTRIENTS, 2021;

FI:5,719; Q1

Velazquez-Suarez, C; Cebrian, R; Gasca-Capote, C; Sorlozano-Puerto, A; Gutierrez-Fernandez, J; Martinez-Bueno, M; Maqueda, M; Valdivia, E

Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-Resistant Staphylococcus aureus.

ANTIBIOTICS-BASEL, 2021;

FI:4,639; Q2

Fuentes, A; Serrano-Conde, E; Roldan, C; Benito-Ruesca, R; Mejias, G; Sampedro, A; March-Rosello, G; Fernandez-Natal, I; Esperalba, J; Rodriguez, MJ; de Aguirre, PM; Salas, C; Roc, ML; Soria, LM; Parra-Grande, M; Montero, MD; Fernandez-Roblas, R; de Luna,

Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021;

FI:3,267; Q3

Barrientos-Duran, A; de Salazar, A; Fuentes-Lopez, A; Serrano-Conde, E; Espadafor, B; Chueca, N; Alvarez-Estevez, M; Garcia, F

Comparison between Aptima (R) assays (Hologic) and the CoBAS (R) 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021;

FI:3,267; Q3

Gomez-Llorente, MA; Martinez-Canavate, A; Chueca, N; Rico, MD; Romero, R; Anguita-Ruiz, A; Aguilera, CM; Gil-Campos, M; Mesa, MD; Khakimov, B; Morillo, JA; Gil, A; Camacho, J; Gomez-Llorente, C

A Multi-Omics Approach Reveals New Signatures in Obese Allergic Asthmatic Children

BIOMEDICINES, 2020;

FI:4,717; Q1

Peris-Torres, C; Plaza-Calonge, MD; Lopez-Dominguez, R; Dominguez-Garcia, S; Barrientos-Duran, A; Carmona-Saez, P; Rodriguez-Manzaneque, JC

Extracellular Protease ADAMTS1 Is Required at Early Stages of Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like Features on Tumor Cells

CANCERS, 2020;

FI:6,126; Q1

Barrientos-Duran, A; de Salazar, A; Alvarez-Estevez, M; Fuentes-Lopez, A; Espadafor, B; Garcia, F

Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2020;

FI:2,837; Q2

Lopez-Martinez, J; Chueca, N; Padial-Molina, M; Fernandez-Caballero, JA; Garcia, F; O'Valle, F; Galindo-Moreno, P

Bacteria associated with periodontal disease are also increased in health

MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2020;

FI:1,596; Q3

Aguilera, A; Alados, JC; Alonso, R; Eiros, JM; Garcia, F

Current position of viral load versus hepatitis C core antigen testing

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2020;

FI:1,654; Q4

Vrancken, B; Cuypers, L; Perez, AB; Chueca, N; Anton-Basantas, J; de la Iglesia, A; Fuentes, J; Pineda, JA; Tellez, F; Bernal, E; Rincon, P; Von Wichman, MA; Fuentes, A; Vera, F; Rivero-Juarez, A; Jimenez, M; Vandamme, AM; Garcia, F

Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes

JOURNAL OF HEPATOLOGY, 2019;

FI:18,946; D1

Alvarez, M; Casas, P; de Salazar, A; Chueca, N; Guerrero-Beltran, C; Rodriguez, C; Imaz, A; Espinosa, N; Garcia-Bujalance, S; Perez-Elias, MJ; Garcia-Alvarez, M; Iribarren, JA; Santos, J; Dalmau, D; Aguilera, A; Vinuesa, D; Gutierrez, F; Pierola, B; Molina, JM; Peraire, J; Portilla, I; Gomez-Sirvent, JL; Olalla, J; Galera, C; Blanco, JR; Riera, M; Garcia-Fraile, L; Navarro, G; Curran, A; Poveda, E; Garcia, F; Moreno, S; Jarrin, I; Dalmau, D; Navarro, ML; Gonzalez, MI; Blanco, JL; Garcia, F; Rubio, R; Iribarren, JA; Gutierrez, F; Vidal, F; Berenguer, J; Gonzalez, J; Alejos, B; Hernando, V; Moreno, C; Iniesta, C; Sousa, LMG; Perez, NS; Munoz-Fernandez, MA; Garcia-Merino, IM; Fernandez, IC; Rico, CG; de la Fuente, JG; Concejo, PP

Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;

FI:5,113; D1

Perez, AB; Chueca, N; Garcia-Deltoro, M; Martinez-Sapina, AM; Lara-Perez, MM; Garcia-Bujalance, S; Aldamiz-Echevarria, T; Vera-Mendez, FJ; Pineda, JA; Casado, M; Pascasio, JM; Salmeron, J; Alados-Arboledas, JC; Poyato, A; Tellez, F; Rivero-Juarez, A; Merino, D; Vivancos-Gallego, MJ; Rosales-Zabal, JM; Garcia, F; Ocete, MD; Simon, MA; Rincon, P; Reus, S; De la Iglesia, A; Garcia-Arata, I; Jimenez, M; Jimenez, F; Hernandez-Quero, J; Galera, C; Balghata, MO; Primo, J; Masia, M; Espinosa, N; Delgado, M; von-Wichmann, MA; Collado, A; Santos, J; Minguez, C; Diaz-Flores, F; Fernandez, E; Bernal, E; De Juan, J; Anton, JJ; Velez, M; Aguilera, A; Navarro, D; Arenas, JI; Fernandez, C; Espinosa, MD; Rios, MJ; Alonso, R; Hidalgo, C; Hernandez, R; Tellez, MJ; Rodriguez, FJ; Antequera, P; Delgado, C; Martin, P; Crespo, J; Becerril, B; Perez, O; Garcia-Herola, A; Montero, J; Freyre, C; Grau, C

High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

JOURNAL OF HEPATOLOGY, 2019;

FI:18,946; D1

Macias, J; Morano, LE; Tellez, F; Granados, R; Rivero-Juarez, A; Palacios, R; Rios, MJ; Merino, D; Perez-Perez, M; Collado, A; Figueruela, B; Morano, A; Freyre-Carrillo, C; Martin, JM; Rivero, A; Garcia, F; Pineda, JA

Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy

JOURNAL OF HEPATOLOGY, 2019;

FI:18,946; D1

Requena, S; Lozano, AB; Caballero, E; Garcia, F; Nieto, MC; Tellez, R; Fernandez, JM; Trigo, M; Rodriguez-Avial, I; Martin-Carbonero, L; Miralles, P; Soriano, V; de Mendoza, C; Rodriguez, C; Vera, M; del Romero, J; Marcaida, G; Ocete, MD; Caballero, E; Aguilera, A; Benito, R; de Lejarazu, RO; Rojo, S; Eiros, JM; Ramos, C; Garcia, J; Paz, I; Trigo, M; Diz, J; Garcia-Campello, M; Rodriguez-Iglesias, M; Hernandez-Betancor, A; Martin, AM; Ramos, JM; Gimeno, A; Sanchez, V; Gomez-Hernando, C; Cilla, G; Perez-Trallero, E; Fernandez-Pereira, L; Niubo, J; Hernandez, M; Lopez-Lirola, AM; Gomez-Sirvent, JL; Force, L; Cabrera, J; Perez, S; Morano, L; Raya, C; Gonzalez-Praetorius, A; Cifuentes, C; Penaranda, M; Nieto, MC; Montejo, JM; Roc, L; Viciana, I; Lozano, AB; Fernandez-Fuertes, E; Fernandez, JM; Garcia-Bermejo, I; Gaspar, G; Tellez, R; Gorgolas, M; Diaz, J; Miralles, P; Perez, L; Valeiro, M; Aldamiz, T; Margall, N; Suarez, A; Rodriguez-Avial, I; Requena, S; Benitez-Gutierrez, L; Cuervas-Mons, V; de Mendoza, C; Barreiro, P; Soriano, V

Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;

FI:5,113; D1

Perez-Parra, S; Alvarez, M; Fernandez-Caballero, JA; Perez, AB; Santos, J; Bisbal, O; Aguilera, A; Rivero, M; Garcia-Fraile, L; Garcia, F

Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018;

FI:5,217; D1

Sorbo, MC; Cento, V; Di Maio, VC; Howe, AYM; Garcia, F; Perno, CF; Ceccherini-Silberstein, F

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 (vol 37, pg 17, 2018)

DRUG RESISTANCE UPDATES, 2018;

FI:11,63; D1

Cuadrado, A; Llerena, S; Cobo, C; Pallas, JR; Mateo, M; Cabezas, J; Fortea, JI; Alvarez, S; Pellon, R; Crespo, J; Echevarria, S; Ayesa, R; Setien, E; Lopez-Hoyos, M; Crespo-Facorro, B; Aguero, J; Chueca, N; Garcia, F; Calleja, JL; Crespo, J

Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018;

FI:10,231; D1

Garrido-Mesa, J; Rodriguez-Nogales, A; Algieri, F; Vezza, T; Hidalgo-Garcia, L; Garrido-Barros, M; Utrilla, MP; Garcia, F; Chueca, N; Rodriguez-Cabezas, ME; Garrido-Mesa, N; Galvez, J

Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution

BRITISH JOURNAL OF PHARMACOLOGY, 2018;

FI:6,81; D1

Cuypers, L; Perez, AB; Chueca, N; Aldamiz-Echevarria, T; Alados, JC; Martinez-Sapina, AM; Merino, D; Pineda, JA; Tellez, F; Espinosa, N; Salmeron, J; Rivero-Juarez, A; Vivancos, MJ; Hontanon, V; Vandamme, AM; Garcia, F

Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

PLOS ONE, 2018;

FI:2,766; Q1

Galindo-Moreno, P; Lopez-Martinez, J; Caba-Molina, M; Rios-Pelegrina, R; Torrecillas-Martinez, L; Monje, A; Mesa, F; Chueca, N; Garcia-Garcia, F; O'Valle, F

Morphological and immunophenotypical differences between chronic periodontitis and peri-implantitis – a cross-sectional study

EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY, 2017;

FI:3,567; D1

Rodriguez-Nogales, A; Algieri, F; Garrido-Mesa, J; Vezza, T; Utrilla, MP; Chueca, N; Garcia, F; Olivares, M; Rodriguez-Cabezas, ME; Galvez, J

Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition

MOLECULAR NUTRITION & FOOD RESEARCH, 2017;

FI:4,323; D1

Aguilera, A; Navarro, D; Rodriguez-Frias, F; Viciana, I; Martinez-Sapina, AM; Rodriguez, MJ; Martro, E; Lozano, MC; Coletta, E; Cardenoso, L; Suarez, A; Trigo, M; Rodriguez-Granjer, J; Montiel, N; de la Iglesia, A; Alados, JC; Vegas, C; Bernal, S; Fernandez-Cuenca, F; Pena, MJ; Reina, G; Garcia-Bujalance, S; Echevarria, MJ; Benitez, L; Perez-Castro, S; Ocete, D; Garcia-Arata, I; Guerrero, C; Rodriguez-Iglesias, M; Casas, P; Garcia, F

Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study)

JOURNAL OF VIRAL HEPATITIS, 2017;

FI:4,122; Q1

Perez-Parra, S; Chueca, N; Alvarez, M; Pasquau, J; Omar, M; Collado, A; Vinuesa, D; Lozano, AB; Yebra, G; Garcia, F

High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach

PLOS ONE, 2017;

FI:2,806; Q1

Masia, M; Padilla, S; Fernandez, M; Barber, X; Moreno, S; Iribarren, JA; Portilla, J; Pena, A; Vidal, F; Gutierrez, F

Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017;

FI:3,935; Q1

Hermans, LE; Svicher, V; Pas, SD; Salpini, R; Alvarez, M; Ben Ari, Z; Boland, G; Bruzzone, B; Coppola, N; Seguin-Devaux, C; Dyda, T; Garcia, F; Kaiser, R; Kose, S; Krarup, H; Lazarevic, I; Lunar, MM; Maylin, S; Micheli, V; Mor, O; Paraschiv, S; Paraskevis, D; Poljak, M; Puchhammer-Stockl, E; Simon, F; Stanojevic, M; Stene-Johansen, K; Tihic, N; Trimoulet, P; Verheyen, J; Vince, A; Weis, N; Yalcinkaya, T; Lepej, SZ; Perno, C; Boucher, CAB; Wensing, AMJ

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)

JOURNAL OF INFECTIOUS DISEASES, 2016;

FI:6,344; D1

Brenner, BG; Thomas, R; Blanco, JL; Ibanescu, RI; Oliveira, M; Mesplede, T; Golubkov, O; Roger, M; Garcia, F; Martinez, E; Wainberg, MA

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;

FI:4,919; D1

Rojas, J; Blanco, JL; Marcos, MA; Lonca, M; Tricas, A; Moreno, L; Gonzalez-Cordon, A; Torres, B; Mallolas, J; Garcia, F; Gatell, JM; Martinez, E

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;

FI:4,919; D1

De Luca, A; Flandre, P; Dunn, D; Zazzi, M; Wensing, A; Santoro, MM; Gunthard, HF; Wittkop, L; Kordossis, T; Garcia, F; Castagna, A; Cozzi-Lepri, A; Churchill, D; De Wit, S; Brockmeyer, NH; Imaz, A; Mussini, C; Obel, N; Perno, CF; Roca, B; Reiss, P; Schulter, E; Torti, C; van Sighem, A; Zangerle, R; Descamps, D

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;

FI:4,919; D1

Hofstra, LM; Sauvageot, N; Albert, J; Alexiev, I; Garcia, F; Struck, D; Van de Vijver, DAMC; Asjo, B; Beshkov, D; Coughlan, S; Descamps, D; Griskevicius, A; Hamouda, O; Horban, A; Van Kasteren, M; Kolupajeva, T; Kostrikis, LG; Liitsola, K; Linka, M; Mor, O; Nielsen, C; Otelea, D; Paraskevis, D; Paredes, R; Poljak, M; Puchhammer-Stockl, E; Sonnerborg, A; Stanekova, D; Stanojevic, M; Van Laethem, K; Zazzi, M; Lepej, SZ; Boucher, CAB; Schmit, JC; Wensing, AMJ

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

CLINICAL INFECTIOUS DISEASES, 2016;

FI:8,736; D1

Monge S; Díez M; Alvarez M; Guillot V; Iribarren JA; Palacios R; Delgado R; Jaén A; Blanco JR; Domingo P; Portilla J; Pérez Elías MJ; Garcia F

Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

Clin Microbiol Infect, 2015;

FI:5,768; D1

Alvarez M; Monge S; Chueca N; Guillot V; Viciana P; Anta L; Rodriguez C; Gomez-Sirvent JL; Navarro G; de los Santos I; Moreno S; García F

Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

Clin Microbiol Infect, 2015;

FI:5,768; D1

Doyle, T; Dunn, DT; Ceccherini-Silberstein, F; De Mendoza, C; Garcia, F; Smit, E; Fearnhill, E; Marcelin, AG; Martinez-Picado, J; Kaiser, R; Geretti, AM

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015;

FI:5,313; D1

Casadella, M; van Ham, PM; Noguera-Julian, M; van Kessel, A; Pou, C; Hofstra, LM; Santos, JR; Garcia, F; Struck, D; Alexiev, I; Kran, AMB; Hoepelman, AI; Kostrikis, LG; Somogyi, S; Liitsola, K; Linka, M; Nielsen, C; Otelea, D; Paraskevis, D; Poljak, M; Puchhammer-Stockl, E; Stanekova, D; Stanojevic, M; Van Laethem, K; Lepej, SZ; Clotet, B; Boucher, CAB; Paredes, R; Wensing, AMJ

Primary resistance to integrase strand-transfer inhibitors in Europe

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015;

FI:5,313; D1

Pineda, JA; Nunez-Torres, R; Tellez, F; Mancebo, M; Garcia, F; Merchante, N; Perez-Perez, M; Neukam, K; Macias, J; Real, LM

Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C

JOURNAL OF INFECTION, 2015;

FI:4,441; Q1

Caracterización de la respuesta de anticuerpos a la vacuna anti-COVID-19 BNT162b2 y sus determinantes

Financiador: CONSEJERÍA DE SALUD Y FAMILIAS

Número de expediente: PI-0198-2021

Tiempo de ejecución: 10/12/2021 - 09/12/2024

IP: FEDERICO GARCIA GARCIA

Enhancing Whole Genome Sequencing (WGS) and/or ReverseTranscription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in Spain.

Financiador: COMISION EUROPEA

Número de expediente: HERA INCUBATOR 2021

Tiempo de ejecución: 03/09/2021 - 02/10/2022

IP: FEDERICO GARCIA GARCIA

CB21/13/00088 FEDERICO GARCÍA GARCÍA ÁREA TEMÁTICA: ENFERMEDADES INFECCIOSAS

Financiador: INSTITUTO DE SALUD CARLOS III

Número de expediente: CB21/13/00088

Tiempo de ejecución: 01/01/2022 - 31/12/2025

IP: FEDERICO GARCIA GARCIA

Programa de Microeliminación de hepatitis C en un centro de inserción social.

Financiador: GILEAD SCIENCES EUROPE LTD

Número de expediente: GILEAD2020-FGG

Tiempo de ejecución: 01/01/2022 - 31/12/2022

IP: FEDERICO GARCIA GARCIA

Hacia la eliminación de la hepatitis C en los pacientes con Trastorno Mental Grave

Financiador: SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA

Número de expediente: GEHEP-2020/FGG

Tiempo de ejecución: 31/12/2020 - 31/12/2021

IP: FEDERICO GARCIA GARCIA

Relevancia Clínica E Impacto Económico de la Correcta Asignación del Genotipo/subtipo del Virus de la Hepatitis C en la Era de Los Antivirales de Acción Directa.

Financiador: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

Número de expediente: PI-0411-2014

Tiempo de ejecución: 31/07/2015 - 30/09/2017

IP: MARTA ALVAREZ ESTEVEZ

Caracterización virológica de los pacientes que no consiguen Respuesta Viral Sostenida a tratamiento con antivirales de acción directa frente al virus de la hepatitis C en regímenes libres de interferón.

Financiador: SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA

Número de expediente: GEHEP-004-FGG

Tiempo de ejecución: 04/07/2017 - 03/07/2018

IP: FEDERICO GARCIA GARCIA

Caracterización virológica de los pacientes que no consiguen Respuesta Viral Sostenida a tratamiento con Antivirales de acción Directa frente al Virus de la Hepatitis C

Financiador: INSTITUTO DE SALUD CARLOS III

Número de expediente: PI15/00713

Tiempo de ejecución: 01/01/2016 - 31/12/2018

IP: FEDERICO GARCIA GARCIA

Implantación de Una Aplicación Web para la Monitorización y Caracterización A Tiempo Real de Los Clusters Con Alta Tasa de Transmisión del Vih en Andalucía Oriental

Financiador: CONSEJERÍA DE SALUD

Número de expediente: PI-0550-2017

Tiempo de ejecución: 01/01/2018 - 31/12/2020

IP: MARTA ALVAREZ ESTEVEZ

RD16/0025/0040 – RED SIDA- FEDERICO GARCÍA GARCÍA

Financiador: INSTITUTO DE SALUD CARLOS III

Número de expediente: RD16/0025/0040

Tiempo de ejecución: 01/01/2017 - 31/12/2021

IP: FEDERICO GARCIA GARCIA

VIGILANCIA EPIDEMIOLOGICA DE LAS RESISTENCIAS PRIMARIAS Y TRASMITIDAS A LOS ANTIRETROVIRALES EN ESPAÑA. ESTUDIO FILOGENÉTICO, FILODINAMICO Y FILOETNICO

Financiador: INSTITUTO DE SALUD CARLOS III

Número de expediente: PI18/00819

Tiempo de ejecución: 01/01/2019 - 31/12/2021

IP: FEDERICO GARCIA GARCIA

CDC- Four-year effectiveness of covid-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study.

Financiador: FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PAZ

Tipo de prueba: ESTUDIO POSAUTORIZACION INDEPENDIENTE

Tiempo de ejecución: 31/08/2021 - 31/08/2025

IP: FEDERICO GARCIA GARCIA

National mapping on carbapenemases in Spain. The CARBA-MAP study

Financiador: MERCK SHARP & DOHME DE ESPAÑA SA

Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL

Tiempo de ejecución: 15/10/2020 - 30/09/2021

IP: NATALIA CHUECA PORCUNA

Efectividad de la doxiciclina en la negativización de la replicación viral en COVID-19. Ensayo clínico aleatorizado de Fase II.

Financiador: FUNDACIÓN PÚBLICA PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL ALEJANDRO OTERO (FIBAO)

Tipo de prueba: ENSAYO CLINICO INDEPENDIENTE

Tiempo de ejecución: 04/12/2020 - 31/12/2021

IP: NATALIA CHUECA PORCUNA

MP13-Resistencias a Antiretrovirales

Líneas de investigación

Redes de investigación

Palabras clave

RUBEN CEBRIAN CASTILLO

ANGEL CARAZO GALLEGO

Mª DOLORES MERIDA DEL CAÑO

JOSE ANTONIO SANCHEZ ALVAREZ

MARTA ALVAREZ ESTEVEZ

NATALIA CHUECA PORCUNA

ADOLFO DE SALAZAR GONZALEZ

ANA FUENTES LOPEZ

FEDERICO GARCIA GARCIA

FERNANDO GARCIA GARCIA

JOSEFA LOPEZ BUENO

Investigación